ZYNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%). View Zynerba Pharmaceuticals' earnings history. All rights reserved. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) issued its quarterly earnings data on Monday, August, 10th. Growing Profit Margin: ZYNE is currently unprofitable. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. These therapetics seek to meet the unmet needs of patients with epilepsy, osteoarthritis, fibromyalgia, peripheral neuropathic pain, and Fragile X syndrome. S&P 500 0.00%. Zynerba Pharmaceuticals (NASDAQ:ZYNE) has been notified that the U.S. FDA planned a meeting in Q4 2020 to discuss the regulatory path forward for … The P/E ratio of Zynerba Pharmaceuticals is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. if the price fails to break 4.09 $ with force the probability of going to seek 3.30 $ is greater. document.write(''); Zynerba Pharmaceuticals has received a consensus rating of Buy. It focuses on research and development of rare and near-rare neuropsychiatric conditions. High Dividend: Unable to evaluate ZYNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. To see all exchange delays and terms of use please see disclaimer. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Identify stocks that meet your criteria using seven unique stock screeners. Analysts Aren't Bullish on Factset Research Systems Stock…Is it a Contrarian Buy? Since then, ZYNE stock has decreased by 16.5% and is now trading at $3.25. Zynerba Pharmaceuticals (NASDAQ:ZYNE) has been notified that the U.S. FDA planned a meeting in Q4 2020 to discuss the regulatory path forward for Zygel™ in children and adolescents with Fragile X Syndrome and a fully methylated FMR1 Gene. It offers Zygel... ZYNE dips into the Ichimoku Cloud #2 before heading back up, to the top of its Cup & Handle (inside the 5 day view). ZYNE underperformed the US Pharmaceuticals industry which returned 9.9% over the past year. High Growth Revenue: ZYNE's revenue (75.1% per year) is forecast to grow faster than 20% per year. Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights. View Zynerba Pharmaceuticals, Inc. ZYNE investment & stock information. According to analysts' consensus price target of $14.33, Zynerba Pharmaceuticals has a forecasted upside of 341.0% from its current price of $3.25. Find market predictions, ZYNE financials and market news. Looking for new stock ideas? View Zynerba Pharmaceuticals' Short Interest. View all competitors. Can You Combat It? 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Shares of ZYNE can be purchased through any online brokerage account. THE STORY OF ZYNE IN A SINGLE PICTURE,DONT NEED TOOLS TO ANALYSE JUST NAKED EYES CAN SEE. View our earnings forecast for Zynerba Pharmaceuticals. to the US Pharmaceuticals industry average. Stable Share Price: ZYNE's share price has been volatile over the past 3 months. (Add your “underperform” vote.). Earnings vs Savings Rate: ZYNE is forecast to remain unprofitable over the next 3 years. Unless specified all financial data is based on a yearly period but updated quarterly. Zynerba Pharmaceuticals has received 53.01% “outperform” votes from our community. Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. ZYNE dips into the Ichimoku Cloud #2 before heading back up, to the top of its Cup & Handle (inside the 5 day view). Copyright © 2018, Standard & Poor’s Financial Services LLC. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. continues to grow or shrink based on historical rates. heavy resistance above from all major moving averages. Currency in USD, Trade prices are not sourced from all markets. ZYNE is forecast to be unprofitable in 3 years. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. Log In. Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. Crypto Market Cap, BTC/USD, ETH/USD, USDT/USD, XRP/USD, Bitcoin, EUR/USD, GBP/USD, USD/JPY, AUD/USD, USD/CAD, USD/CHF, Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc, S&P 500, Nasdaq 100, Dow 30, Russell 2000, U.S. Dollar Index, Bitcoin Index, Gold, Silver, Crude Oil, Natural Gas, Corn, Bitcoin, US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y, Nice move today on good volume .